A virus vector based on Canine Herpesvirus for vaccine applications in canids

Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens

Throughout the past few decades, numerous viral species have been generated as vaccine vectors. Every viral vector has its own distinct characteristics. For example, the family herpesviridae encompasses several viruses that have medical and veterinary importance. Attenuated herpesviruses are developed as vectors to convey heterologous immunogens targeting several serious and crucial pathogens. Some of these vectors have already been licensed for use in the veterinary field. One of their prominent features is their capability to accommodate large amount of foreign DNA, and to stimulate both cell-mediated and humoral immune responses. A better understanding of vector-host interaction builds up a robust foundation for the future development of herpesviruses-based vectors. At the time, many molecular tools are applied to enable the generation of herpesvirus-based recombinant vaccine vectors such as BAC technology, homologous and two-step en passant mutagenesis, codon optimization, and the CRISPR/Cas9 system. This review article highlights the most important techniques applied in constructing recombinant herpesviruses vectors, advantages and disadvantages of each recombinant herpesvirus vector, and the most recent research regarding their use to control major animal diseases.

Prospects for immunocontraception in the European red fox (Vulpes vulpes)

The European red fox is an introduced pest species in Australia for which improved means of control are urgently needed. Research efforts have focussed recently on the development of novel biological control methods to reduce the serious impact this species continues to have on both native fauna and the sheep industry. The ultimate goal has been to generate an antifertility vaccine for use on foxes that relies on a process termed ‘immunocontraception’. A variety of proteins derived from sperm and oocytes, together with different delivery vectors, have been experimentally assessed for their ability to induce immunocontraceptive responses in foxes. Vaccine vectors screened have included Salmonella typhimurium, vaccinia virus and canine herpesvirus but suppression of fertility has yet to be achieved with any combination of antigen and delivery vector. Downregulation of fox mucosal antibodies during oestrus, lack of vector replication and low antibody responses to the target antigens have been the main constraints in successful fertility control. The fox is not well known as an experimental animal and the logistics of dealing with this difficult-to-handle species proved to be a major challenge when compared with other species, such as rabbits and mice. Despite these difficulties, research on fox immunocontraception has generated important insights into the reproductive biology, husbandry, biology and basic immunology of viral vectors in European red foxes. This information represents a valuable knowledge base should antifertility vaccination for foxes be revisited in the future.